• Return to Headlines

Earnings Watch: Nektar Therapeutics is Scheduled to Report its Quarterly Results in 2 days (NKTR)

Written on Mon, 07/26/2010 - 3:53am
By Chip Brian

Analysts, on average, expect Nektar Therapeutics (NASDAQ:NKTR) to report a loss of $0.08 on sales of $37 million on July 28, 2010.
For the full year, analysts expect the company to post a loss of $0.27. In the year-ago period, the company reported a loss of $0.35 on sales of $13 million.
In the previous quarter, the company reported a loss of $0.07, topping consensus estimates for a loss of $0.09.
SmarTrend is bearish on shares of Nektar Therapeutics and our subscribers were alerted to Sell on April 26, 2010 at $13.76. The stock has fallen 6.9% since the alert was issued.

Keywords: nektar therapeutics earnings preview

Ticker(s): NKTR

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.